医学
嗜酸性
免疫学
鼻窦炎
哮喘
中耳炎
单克隆抗体
炎症
美波利祖马布
过敏
白细胞介素13
过敏性炎症
抗体
作者
Ayumi Chikumoto,Keiji Oishi,Kazuki Hamada,Tsunahiko Hirano,Tomoyuki Kakugawa,Keiko Kanesada,Kazuto Matsunaga
出处
期刊:Biomolecules
[MDPI AG]
日期:2022-03-30
卷期号:12 (4): 522-522
摘要
Type 2 (T2) inflammation plays an important role in the pathogenesis of allergic diseases such as asthma, eosinophilic chronic rhinosinusitis (ECRS), or eosinophilic otitis media (EOM). Currently, in severe asthma with the T2 phenotype, biologics targeting mediators of T2 inflammation dramatically improve the management of severe asthma. While treatment with a single biologic is common, little is known about cases of the sequential use of two biologics. Here, we report a case of severe asthma with refractory ECRS and EOM in which total control of these allergic diseases could not be achieved with a single biologic but could be achieved via the sequential use of the anti-IL-5 receptor antibody and human anti-IL-4/13 receptor monoclonal antibody. It is suggested that it is necessary to control multiple T2 inflammatory pathways to achieve total control of severe allergic diseases. Sequential biotherapy may help solve the clinical challenges associated with single-agent molecular-targeted therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI